Trial reportEuropean urology focus2021
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.
Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in European urology focus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- PSMA PET/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?Annals of nuclear medicine · 2026Pooled it
- Detection of Biochemically Recurrent Prostate Cancer with [Tomography (Ann Arbor, Mich.) · 2023Pooled it
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- [European urology · 2026Trial
- PET imaging utilization and trends in Germany: a comprehensive survey.European journal of nuclear medicine and molecular imaging · 2025Article
- Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis.European journal of nuclear medicine and molecular imaging · 2025Article
- Role of PSMA PET/CT in imaging and management of prostate cancer.Current opinion in oncology · 2025Review
- cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.EJNMMI research · 2024Article
- Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.European urology open science · 2024Article
- Impact of PSMA PET on Prostate Cancer Management.Current treatment options in oncology · 2024Review
- Article
- Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.Cancers · 2023Article
- Clinical practice in prostate PET imaging.Therapeutic advances in medical oncology · 2023Review
- The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.Cancers · 2022Article
- Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.BJU international · 2022Article
- Event-free survival afterEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT.Radiation oncology (London, England) · 2022Article
- PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.International journal of molecular sciences · 2022Review
- PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: jcalais@mednet.ucla.edu.
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Amar U KishanJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Kiara M BookerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; San Francisco VA Medical Center, San Francisco, CA, USA.
Wolfgang P FendlerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
David ElashoffJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Nicholas G NickolsJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6MMELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2MQualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7MNCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA235741
Abstract
The purpose of this randomized trial is to evaluate the success rate of salvage radiation therapy for recurrence of prostate cancer after radical prostatectomy, with and without planning based on prostate-specific membrane antigen positron emission tomography/computed tomography. Enrollment has been completed and patients are being followed for 5yr.
Indexed as
ProstateProstatic NeoplasmsGallium IsotopesGallium RadioisotopesHumansMaleNeoplasm Recurrence, LocalPositron-Emission TomographyProstate-Specific AntigenRecurrenceGallium IsotopesGallium RadioisotopesProstate-Specific Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.